We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Active Surveillance Study for Oral Contraceptives (LASS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00676065
First Posted: May 12, 2008
Last Update Posted: November 19, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Bayer
Information provided by (Responsible Party):
Juergen Dinger, MD, PhD, Center for Epidemiology and Health Research, Germany
May 8, 2008
May 12, 2008
November 13, 2014
November 19, 2014
November 19, 2014
February 2001
March 2011   (Final data collection date for primary outcome measure)
  • Arterial Thromboembolism [ Time Frame: Within 10 years ]
    Arterial thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.
  • Venous Thromboembolism [ Time Frame: Within 10 years ]
    Venous thromboembolism associated with the use of oral contraceptives containing drospirenone or levonorgestrel or other progestogens.
  • Breast Cancer [ Time Frame: Within 10 years ]
    Breast cancer associated with the use of hormonal contraceptives either containing both drospirenone (DRSP) and ethinylestradiol (EE), levonorgestrel (LNG) or any other hormonal contraceptive without DRSP.
Arterial Thromboembolism
Complete list of historical versions of study NCT00676065 on ClinicalTrials.gov Archive Site
Not Provided
gynecological cancer
Not Provided
Not Provided
 
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
Long-term Active Surveillance Study for Oral Contraceptives (LASS)
The objective of this study is to characterize and compare the risks of long-term use of oral contraceptives containing drospirenone and of other established oral contraceptives.

The LASS Study is a large, multinational, prospective, controlled, non-interventional, long-term cohort study that follows a series of cohorts. The cohorts consist of new users (first-ever users, switchers and restarters) of three different groups of oral contraceptives (OCs): OCs containing drospirenone (DRSP), OCs containing levonorgestrel (LNG) and OCs containing other progestogens. A "non-interference" approach is used to provide standardized, comprehensive, reliable information on these groups of OCs under routine medical conditions.

The main clinical outcomes of interest for the long-term follow-up are arterial and venous thromboembolism as well as breast cancer. Regular, active contacts with the cohort members (=active surveillance) provide all necessary information on health-related events or changes in health status.

The study is based on the existing long-term EURAS cohorts who are still in follow-up. LASS succeeds EURAS and prolongs the follow-up period for another five years. Total follow-up time of members of the long-term cohorts will be between 6 and 10 years. By means of annual contacts almost all relevant clinical outcomes will be captured. This will be accomplished by contacting the relevant physicians and by reviewing relevant source documents in the case of relevant clinical outcomes.

Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Women attending offices of oral contraceptives prescribing physicians
  • Arterial Thromboembolism
  • Venous Thromboembolism
  • Breast Cancer
Not Provided
  • 1
    Women who take oral contraceptives containing drospirenone
  • 2
    Women who take oral contraceptives containing levonorgestrel
  • 3
    Women who take oral contraceptives containing other progestogens
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58303
December 2011
March 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Women who are prescribed an oral contraceptive and who are new users (first-ever users, switchers or restarters) of the formulation

Exclusion Criteria:

  • Women who do not consent to participate in the study
Sexes Eligible for Study: Female
Child, Adult, Senior
Yes
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00676065
ZEG2006_03
Yes
Not Provided
Not Provided
Juergen Dinger, MD, PhD, Center for Epidemiology and Health Research, Germany
Center for Epidemiology and Health Research, Germany
Bayer
Principal Investigator: Juergen Dinger, MD, PhD Center for Epidemiology and Health Research Berlin, Germany
Center for Epidemiology and Health Research, Germany
November 2014